[go: up one dir, main page]

GT201500046A - Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d - Google Patents

Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d

Info

Publication number
GT201500046A
GT201500046A GT201500046A GT201500046A GT201500046A GT 201500046 A GT201500046 A GT 201500046A GT 201500046 A GT201500046 A GT 201500046A GT 201500046 A GT201500046 A GT 201500046A GT 201500046 A GT201500046 A GT 201500046A
Authority
GT
Guatemala
Prior art keywords
hepatitis
treatment
infections
methods
hetigenis
Prior art date
Application number
GT201500046A
Other languages
English (en)
Inventor
Bazinet Michael
Vaillant Andrew
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of GT201500046A publication Critical patent/GT201500046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBE UN MÉTODO PARA EL TRATAMIENTO DE LA INFECCIÓN POR VHB O VHB / HDV CO-INFECCIÓN, COMPRENDIENDO EL MÉTODO ADMINISTRAR A UN SUJETO EN NECESIDAD DE TRATAMIENTO UN AGENTE DE PRIMERA FARMACÉUTICAMENTE ACEPTABLE QUE ELIMINA EL ANTÍGENO DE SUPERFICIE DE HEPATITIS B DE LA SANGRE Y UN SEGUNDO FARMACÉUTICAMENTE ACEPTABLE AGENTE QUE ESTIMULA LA FUNCIÓN INMUNE.
GT201500046A 2012-08-30 2015-02-27 Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d GT201500046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695040P 2012-08-30 2012-08-30
US201261703816P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
GT201500046A true GT201500046A (es) 2016-04-13

Family

ID=50182316

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500046A GT201500046A (es) 2012-08-30 2015-02-27 Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d

Country Status (23)

Country Link
US (4) US9133458B2 (es)
EP (1) EP2890403A4 (es)
JP (2) JP6270846B2 (es)
KR (2) KR20150046309A (es)
CN (1) CN104837501B (es)
AU (1) AU2013308045B2 (es)
BR (1) BR112015003985A2 (es)
CA (1) CA2883785C (es)
CL (1) CL2015000499A1 (es)
CR (1) CR20150107A (es)
CU (1) CU20150018A7 (es)
DO (1) DOP2015000041A (es)
EC (1) ECSP15007345A (es)
GT (1) GT201500046A (es)
IL (1) IL237173B (es)
IN (1) IN2015DN01087A (es)
MX (1) MX361522B (es)
MY (1) MY172785A (es)
NZ (1) NZ705730A (es)
PH (1) PH12015500361B1 (es)
SG (1) SG11201501255PA (es)
TW (1) TWI620568B (es)
WO (1) WO2014032176A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210840T1 (hr) 2012-05-18 2021-08-06 Replicor Inc. Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
BR112015003985A2 (pt) 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d
HUE064449T2 (hu) 2014-07-10 2024-03-28 Replicor Inc Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
US20160175245A1 (en) * 2014-12-19 2016-06-23 Mycotoxins Therapy, Llc Treatment of diseases associated with mold and mycotoxin exposure
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
WO2017015175A1 (en) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
CN108350455A (zh) * 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
SG11201805729SA (en) * 2016-01-08 2018-08-30 Arbutus Biopharma Corp Therapeutic compositions and methods for treating hepatitis b
HRP20210862T1 (hr) 2016-02-19 2021-09-17 Eiger Biopharmaceuticals, Inc. Liječenje infekcije hepatitis delta virusom pomoću interferona lambda
AR111908A1 (es) * 2017-05-31 2019-08-28 Arbutus Biopharma Corp Composiciones terapéuticas y métodos de tratamiento de hepatitis b
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
MX2021000404A (es) 2018-07-13 2021-03-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de rtel1.
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
KR102880569B1 (ko) 2018-12-19 2025-11-06 후맙스 바이오메드 에스에이 B형 간염 바이러스를 중화하는 항체 및 이의 용도
LT3897672T (lt) 2018-12-20 2023-11-10 Vir Biotechnology, Inc. Kombinuota hbv terapija
CA3163490A1 (en) * 2019-12-24 2021-07-01 F. Hoffman-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030954A (en) 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20040054156A1 (en) 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
CA2254931C (en) * 1996-06-11 2007-04-10 Yeda Research And Development Co. Ltd. Human monoclonal antibodies to the hepatitis b surface antigen
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
DE19725803C1 (de) 1997-06-18 1999-02-11 Deutsches Krebsforsch HBV-gerichtete Antisense-Nukleinsäuren
US6670342B2 (en) 2000-03-29 2003-12-30 Georgetown University Method of treating hepatitis delta virus infection
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
EP3470518A1 (en) 2003-06-12 2019-04-17 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
EP2512491B1 (en) * 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
CA2746981A1 (en) * 2010-08-05 2012-02-05 Replicor Inc. Methods for inhibition of apolipoprotein h
KR101606495B1 (ko) 2010-08-20 2016-03-28 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
WO2012047856A2 (en) * 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
EA029137B1 (ru) 2011-04-21 2018-02-28 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита в (hbv)
KR102167524B1 (ko) 2011-06-30 2020-10-20 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
HRP20210840T1 (hr) 2012-05-18 2021-08-06 Replicor Inc. Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
BR112015003985A2 (pt) 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d

Also Published As

Publication number Publication date
TW201408309A (zh) 2014-03-01
US9133458B2 (en) 2015-09-15
CA2883785C (en) 2020-08-18
JP2015528449A (ja) 2015-09-28
IL237173A0 (en) 2015-04-30
US20140369963A1 (en) 2014-12-18
EP2890403A1 (en) 2015-07-08
IN2015DN01087A (es) 2015-06-26
CA2883785A1 (en) 2014-03-06
IL237173B (en) 2020-04-30
WO2014032176A1 (en) 2014-03-06
CL2015000499A1 (es) 2015-06-05
JP2018039834A (ja) 2018-03-15
CU20150018A7 (es) 2016-02-29
NZ705730A (en) 2016-06-24
US9200283B2 (en) 2015-12-01
MX361522B (es) 2018-12-10
DOP2015000041A (es) 2015-04-30
KR20150046309A (ko) 2015-04-29
US20140065102A1 (en) 2014-03-06
US20160263143A1 (en) 2016-09-15
AU2013308045B2 (en) 2018-10-04
KR102025679B1 (ko) 2019-09-26
JP6270846B2 (ja) 2018-01-31
CR20150107A (es) 2015-04-06
HK1210022A1 (en) 2016-04-15
BR112015003985A2 (pt) 2017-08-08
AU2013308045A1 (en) 2015-04-02
ECSP15007345A (es) 2015-12-31
PH12015500361A1 (en) 2015-04-20
US9533003B2 (en) 2017-01-03
KR20170127578A (ko) 2017-11-21
MX2015002491A (es) 2015-06-05
EP2890403A4 (en) 2016-03-09
TWI620568B (zh) 2018-04-11
CN104837501A (zh) 2015-08-12
PH12015500361B1 (en) 2015-04-20
SG11201501255PA (en) 2015-03-30
MY172785A (en) 2019-12-12
US20140369962A1 (en) 2014-12-18
US9284556B2 (en) 2016-03-15
CN104837501B (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
IL250389A0 (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
MX388743B (es) Conjugados oligonucleótido-péptido.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
WO2015084741A3 (en) Methods of treating hepatitis c virus infection in subjects with cirrhosis
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
IL240283A (en) Topical veterinary compositions comprising an isoxazoline active agent, methods and uses thereof for treating or preventing a parasitic infection or infestation in a mammal
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
EA201291158A1 (ru) Комбинированные вакцины с синтетическими наноносителями
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
EA201500701A1 (ru) Способ создания вакцины против микоплазм
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
MX369039B (es) Vacuna contra el circovirus porcino tipo 2.
WO2014160088A3 (en) Treating hepatitis b virus infections
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
EA201500273A1 (ru) Способы лечения инфекций вирусом гепатита в и гепатита d
TH148307A (th) การรักษาการติดเชื้อไวรัสตับอักเสบ c โดยใช้อะลิสพอริเวียร์
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
BR112013025934A2 (pt) tratamento de infecção pelo vírus da hepatite c com alisporivir
RU2013143983A (ru) Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота
UA84283U (ru) Способ профилактики обострений вирусного гепатита а (вга) у взрослых